Shanghai Medicilon Inc.

Medicilon provide  preclinical animal studies  for clients. Animal studies of drug efficacy are an important resource for designing and performing clinical trials. They provide evidence of a drug’s potential clinical utility, inform the design of trials and establish the ethical basis for testing drugs in human. Several recent studies suggest that many preclinical investigations are withheld from publication. Such non-reporting likely reflects that private drug developers have little incentive to publish preclinical studies. However, it potentially deprives stakeholders of complete evidence for making risk/benefit judgments and frustrates the search for explanations when drugs fail to recapitulate the promise shown in animals. Preclinical Trial  – A laboratory test of a new drug or a new medical device, usually done on animal subjects, to see if the hoped-for treatment really works and if it is safe to test on humans. Preclinical Animal Studies • In Vitro Toxic...

Medicilon's toxicology department has professional teams with rich experience in toxicology studies. We offer high-quality data and rapid turnaround period to support drug discovery and development. Our toxicological studies are conducted in various animal species. The toxicological evaluation from dose design, in-life studies to histology and pathology testing along with toxicokinetics studies are all compliant with GLP or NON-GLP standards. Our study platform is certified as one of the Shanghai Public Service Research Platforms. Animal Facilities 50,000 Sq. ft.  total  area 12,500 Sq. ft. for function area 12,500 Sq. ft. for Canine housing: maximum capability for 350 canines 12,500 Sq. ft. for Nonhuman Primate housing: maximum capability for 400 NHPs 12,500 Sq. ft. for Barrier system for Rodent housing: Separate SPF and non-SPF area; maximum capability for 5000 animals of SPF area and 500 animals of non-SPF area Design and Operation of the facility are under in...

Medicilon's Pharmacology department functions in accordance with the needs of our customers for a variety of effective animal models used to detect drug effectiveness. We offer non-human primates, dogs, mice, and rats, rabbits, guinea pigs, amongst others in our services. At present, we have various proven effective animal models, furthermore, our staff’s rich experience operate with strong theoretical basis is while still being flexible enough for custom development of various types of models to meet the requirements of our clients. View more about medicilon's service, www.medicilon.com

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites   On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

We utilize medicinal chemistry efficiently and cost-effectively to progress our client’s drug discovery projects to candidate nomination, preclinical development, and IND. Hit to lead and/or lead optimization Rational drug design Computer aided drug design (CADD) Structure Activity Relationship (SAR) campaign Final lead optimization and candidate nomination Process development of preclinical candidate Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

Medicilon ’s Preclinical department has extensive and professional knowledge in drug metabolism/pharmacokinetics, pharmacology studies as well as toxicology . We offer high-quality and  cost-effective data with rapid turnaround time to support drug development, preclinical studies and clinical research. Our services cover various aspects of preclinical services, including protocol designing, in-life studies, sample analysis, professional data analysis, IACUC review, and preparation of documents for IND filing. Over 50%  of our employees have MS and PhD degrees, and over 10% of our employees have significant foreign education and/or working experiences. Medicilon and MPI Research established a joint venture from 2008-2010 to set up a state-of-the-art 50,000 Sq. ft. animal facility fully accredited by AAALAC and in compliance with US GLP and China FDA GLP. Our services facilitate the evaluation of the safety and marketing of life-changing compounds for our clients.